Metrifonate treatment of the cognitive deficits of Alzheimer's disease

Neurology

Volumn 50, Issue 5, 1998, Pages 1214-1221

  Cummings, Jeffrey L ^a   Cyrus, P A ^b   Bieber, F ^b   Mas, J ^b   Orazem, J ^b   Gulanski, B ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METRIFONATE;

ABDOMINAL PAIN; AGED; ALZHEIMER DISEASE; ARTICLE; BRADYCARDIA; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLATULENCE; HUMAN; LEG CRAMP; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME;

EID: 0031842292     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.50.5.1214     Document Type: Article

References (39)

1. Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. J Am Med Assoc 1989; 262:2551-2556.
2. Ernst R, Hay J. The U.S. economic and social costs of Alzheimer's disease revisited. Am J Public Health 1994;84:1261-1264.
3. Whyte S, Beyreuther K, Masters CL. Rational therapeutic strategies for Alzheimer's disease. In: Calne DB, ed. Neurodegenerative diseases. Philadelphia: WB Saunders, 1994.
4. Davies P. Studies on the neurochemistry of central cholinergic systems in Alzheimer's disease. In: Katzman R, Terry RD, Bike KL, eds. Alzheimer's disease: senile dementia and related disorders. New York: Raven Press, 1978:453-459.
5. Whitehouse PJ, Price DL, Clark AW, et al. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981;10:122-126.
6. Drachman DA. Memory and cognitive function in man: does the cholinergic system have a specific role? Neurology 1977; 27:783-790.
7. Sunderland T, Tariot PN, Cohen RM, et al. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. Arch Gen Psychiatry 1987;44:418-426.
8. Wilcock GK, Esiri MM, Bowen DM, Smith CCT. Alzheimer's disease. Correlation of cortical cholinergic acetyltransferase activity with the severity of dementia and histopathological abnormalities. J Neurol Sci 1982;57:407-417.
9. Galasko DR, Thai LJ. Cholinomimetic agents. In: Cummings JL Miller BL, eds. Alzheimer's disease. Treatment and long-term management. New York: Marcel Dekker, 1990:23-36.
10. Farlow M, Gracon SI, Hershey LA, et al. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992;268:2523-2529.
11. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-991.
12. Rogers SL, Friedhoff LT, and the Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicenter, randomized, double-blind, placebo-controlled trial. Dementia 1996;7:293-303.
13. Reiner RE, Krauthacker B, Simeon V, Skrinjaric-Spoiler M. Mechanisms of inhibition in vitro of mammalian acetylcholinesterase and cholinesterase in solutions of O,O-dimethyl 2,2,2-trichloro-1-hydroxyethyl phosphonate (trichorphon). Biochem Pharmacol 1975;24:717-722.
14. Riekkinen P Jr, Schmidt B, Stefanski R, Kuitunen J, Riekkinen M. Metrifonate improves spatial navigation and avoidance behaviour in scopolamine-treated, medial septum-lesioned and aged rats. Eur J Pharmacol 1996;309:121-130.
15. van der Staay FJ, Hinz V, Schmidt B. Effects of metrifonate on escape and avoidance learning in young and aged rats. Behav Pharmacol 1996;76:56-64.
16. Becker RE, Colliver J, Elble R, et al. Effects of metrifonate, a long-acting cholinesterase inhibitor, in Alzheimer disease: report of an open trial. Drug Dev Res 1990;19:425-434.
17. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:39-44.
18. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
19. Rosen WG, Terry RD, Fuld P, et al. Pathological verification of Ischemia Score in differentiation of dementias. Ann Neurol 1980;7:486-488.
20. Reisberg B, Ferris SH, De Leon MJ, Crook T. A Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136-1139.
21. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd ed., revised. Washington, DC: American Psychiatric Association, 1987.
22. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
23. Knopman DS, Knapp MJ, Gracon SI, Davis CS. The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. Neurology 1994;44:2315-2321.
24. Schwartz GE. Development and validation of the Geriatric Evaluation by Relative's Rating Instrument (GERRI). Psychol Reports 1983;53:479-488.
25. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179-186.
26. Cerf J, Lebrun A, Dierichx J. A new approach to helminthiasis control: the use of an organophosphorus compound. Am J Trop Med Hyg 1962;11:514-517.
27. Anand R, Gharabawi G, Enz A. Efficacy and safety results of the early phase studies of Exelon (ENA-713) in Alzheimer's disease: an overview. J Drug Dev Clin Pract 1996;8:2-8.
28. Hinz V, Grewig S, Schmidt BH. Metrifonate and dichlorvos: effects of a single oral administration on cholinesterase activity in rat brain and blood. Neurochem Res 1996;21:339-345.
29. Holmstedt B, Nordgren I, Sandoz M, Sundwall A. Metrifonate. A summary of toxicological and pharmacological information available. Arch Toxicol 1978;41:3-29.
30. Nordgren I, Holmstedt B. Metrifonate: a review. In: Giacobini R, Becker R, eds. Current research in Alzheimer therapy. New York: Taylor and Francis, 1988:281-288.
31. Tracy JW, Webster LT Jr. Drugs used in the chemotherapy of helminthiasis. In: Hardman JG, Limbird LE, Molinoff PB, Gilman AG, eds. Goodman and Gilman's the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill, 1996: 1009-1026.
32. Hallak M, Giacobini E. A comparison of the effects of two inhibitors on brain cholinesterase. Neuropharmacology 1987; 26:521-530.
33. Soininen H, Unni L, Shillcut S. Effect of acute and chronic cholinesterase inhibition on biogenic brain amines in rat brain. Neurochem Res 1990;15:1185-1190.
34. Hinz VC, Grewig S, Schmidt BH. Metrifonate induces cholinesterase inhibition exclusively via slow release of dichlorvos. Neurochem Res 1996;21:331-337.
35. Pacheco G, Palacios-Esquivel R, Moss DE. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease. Selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase. J Pharmacol Exp Ther 1995;274:767-770.
36. Moriearty PL, Becker RE. Inhibition of human brain and red blood cell acetylcholinesterase (AChE) by heptylphysostigmine (HPTL). Meth Find Clin Pharmacol 1992;14:615-621.
37. Reiner E, Plastina R. regeneration of cholinesterase activities in humans and rats after inhibition by O,O-dimethyl-2,2-dichlorovinylphosphate. Toxicol Appl Pharmacol 1979;49:451-454.
38. Aronson MK, Post DC, Guastadisegni P. Dementia, agitation and care in the nursing home. J Am Geriatr Soc 1993;41:507-512.
39. Rovner BL, Stelle CD, German P, et al. Psychiatric diagnosis and uncooperative behavior in nursing homes. J Geriatr Psychiatry Neurol 1992;5:102-105.